Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Cirrus HD-OCT (Carl Zeiss Meditec Inc.) for diagnosis of glaucoma. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2012 Authors' conclusions Glaucoma describes a group of eye diseases characterized by damage to the optic nerve, leading to irreversible vision loss and blindness. Glaucoma affects more than 60 million people worldwide and approximately 2.2 million people in the United States. Glaucoma usually begins with subtle loss of peripheral vision and, if left undiagnosed and untreated, will eventually progress to complete blindness. Because the visual impairment from glaucoma is irreversible, early detection of the disease is important. The retinal nerve fiber layer (RNFL) thickness, formed by the expansion of the fibers of the optic nerve, is a valuable parameter in the diagnosis and follow-up of glaucoma. Optical coherence tomography (OCT) is a technology developed to objectively measure the thickness of the RNFL in a noninvasive manner. Standard time-domain OCT is typically performed with the Stratus OCT device manufactured by Carl Zeiss Meditec Inc. A newer technology from the same manufacturer, the Cirrus high-definition (HD) OCT, is a spectral-domain OCT instrument. Indexing Status Subject indexing assigned by CRD MeSH Glaucomas; Reproducibility of Results; Tomography, Optical Coherence Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32013000220 Date abstract record published 27/03/2013 |